[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR086931A1 - Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth - Google Patents

Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth

Info

Publication number
AR086931A1
AR086931A1 ARP120102111A ARP120102111A AR086931A1 AR 086931 A1 AR086931 A1 AR 086931A1 AR P120102111 A ARP120102111 A AR P120102111A AR P120102111 A ARP120102111 A AR P120102111A AR 086931 A1 AR086931 A1 AR 086931A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
phenyl
cycloalkyl
fluoroalkyl
Prior art date
Application number
ARP120102111A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR086931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR086931A1 publication Critical patent/AR086931A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Composiciones farmacéuticas que comprenden tales compuestos y métodos de uso de los compuestos para el tratamiento de enfermedades o afecciones asociadas con la estimulación incontrolada o inapropiada de la función de CRTH2.Reivindicación 1: Un compuesto de la fórmula (1) o una sal o éster farmacéuticamente aceptable del mismo, en la que R1 es (i) H, (ii) alquilo C1-4, (iii) alquenilo C2-4, (iv) cicloalquilo C3-7, (v) -(alquileno C1-3)-R9, en la que R9 es cicloalquilo C3-7, fenilo o un heteroarilo de 5 a 6 miembros que contiene de 1 a 2 heteroátomos seleccionados entre el grupo que consiste en N, O y S, (vi) fenilo, (vii) -C(O)-R5, en la que R5 es alquilo C1-6, cicloalquilo C3-6, fenilo, (viii) o un grupo de la formula (2), en la que v es 1, 2 ó 3; R2 es (i) -Q-W-V, en la que Q es -C(O)-, -C(O)O-, -C(O)N(H)-, -C(O)N(alquil C1-6)-, -CH2-, o -S(O)2-; W es (a) alquileno C1-8, en la que dicho alquileno de W está sin sustituir o sustituido con 1 a 2 flúor; (b) -CH=CH-, o (c) un fenileno de la fórmula (3), en el que dicho fenileno está sin sustituir o sustituido con 1 a 2 halo; V es (a) -CO2H, (b) tetrazolilo, o (c) un grupo de la fórmula (4), en la que RV1 se selecciona entre el grupo que consiste en alquilo C1-6, cicloalquilo C3-6 y fenilo; (ii) -M-CO2H, en la que M es seleccionado del grupo de fórmulas (5), en la que w es 0, 1, 2 ó 3; XA es S u O; XB es N o C(H); con la condición de que cuando R1 sea -C(O)-R5, entonces R2 sea -CH2-W-V; Y es -C(O)-, -S(O)2-, o un grupo de la fórmula (6), en la que XA1 es S u O; y XB1 es N o C(H); Z es (i) ausente, (ii) -alquileno C1-6-, (iii) -O-, (iv) -O-(alquileno C1-6)-, en la que dicho -O-(alquileno C1-6)- de Z está sin sustituir o sustituido con 1 a 3 flúor, (v) -N(H)-, o (vi) un grupo de la fórmula (7), en la que r es 1, 2, 3 ó 4; E es (i) fenilo, (ii) naftilo, (iii) tetrahidronaftilo, (iv) indanilo, (v) heteroarilo mono- o bicíclico de 5 a 10 miembros que contiene de uno a tres heteroátomos seleccionados entre el grupo que consiste en N, O y S, (vi) heterociclenilo mono- o bicíclico de 5 a 10 miembros que contiene de uno a tres heteroátomos seleccionados entre el grupo que consiste en N, O y S, en la que dicho fenilo, naftilo, tetrahidronaflilo, indanilo, heteroarilo de 5 a 10 miembros o heterociclenilo de 5 a 10 miembros de E está sin sustituir o sustituido con uno a tres restos R4, en los que cada R4 se selecciona entre el grupo que consiste en alquilo C1-6, alcoxi C1-3, -CN, halo, hidroxilo, fluoroalquilo C1-3, -O-(fluoroalquilo C1-3), -S-(alquilo C1-3), -S-(fluoroalquilo C1-3), cicloalquilo C3-7, R4, -O-R4a, o heterociclilo de 5 a 6 miembros que contiene 1 ó 2 heteroátomo seleccionado entre el grupo que consiste en N, O y S; R4a es fenilo o un anillo heteroarilo de 5 a 6 miembros que contiene de uno a dos heteroátomos seleccionados entre el grupo que consiste en N, O y S; en la que R4a está sin sustituir o sustituido con uno a dos restos seleccionados independientemente entre el grupo que consiste en alquilo C1-6, alcoxi C1-3, halo, -CN, fluoroalquilo C1-3, -O-(fluoroalquilo C1-3), -S-(fluoroalquilo C1-3) y -SO2-(alquilo C1-3), o, en la que dos restos R4 están sustituidos en los átomos de carbono cercanos de E, los dos restos R4 junto con los átomos de carbono a los que están unidos forman un anillo dioxolano; (vii) cicloalquilo C3-7, o (viii) alquilo C1-6; n es 0, 1 ó 2; cada caso de R7 es independientemente halo, fluoroalquilo C1-3, hidroxi(alquilo C1-3), -CN, fenilo, o un heteroarilo de 5 a 6 miembros que contiene de 1 a 2 heteroátomos seleccionados entre el grupo que consiste en N, O y S, en la que dicho fenilo o heteroarilo de R7 está sin sustituir o sustituido independientemente con 1 a 2 halo; t es 0, 1, 2 ó 3; cada caso de R8 es independientemente alquilo C1-3, alquenilo C2-3 o flúor; u es 0, 1 ó 2; y R8a es H o alquilo C1-6.
ARP120102111A 2011-06-17 2012-06-14 Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth AR086931A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161498345P 2011-06-17 2011-06-17

Publications (1)

Publication Number Publication Date
AR086931A1 true AR086931A1 (es) 2014-01-29

Family

ID=47357455

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120102111A AR086931A1 (es) 2011-06-17 2012-06-14 Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth

Country Status (25)

Country Link
US (2) US20140128367A1 (es)
EP (1) EP2720545B1 (es)
JP (1) JP5629403B2 (es)
KR (1) KR101599157B1 (es)
CN (1) CN103763924B (es)
AR (1) AR086931A1 (es)
AU (1) AU2012271661B8 (es)
BR (1) BR112013032557A2 (es)
CA (1) CA2838731C (es)
CL (1) CL2013003625A1 (es)
CO (1) CO6821958A2 (es)
CR (1) CR20130670A (es)
DO (1) DOP2013000306A (es)
EA (1) EA025100B1 (es)
EC (1) ECSP14013156A (es)
ES (1) ES2613644T3 (es)
IL (1) IL229508A0 (es)
MA (1) MA35188B1 (es)
MX (1) MX2013014900A (es)
NI (1) NI201300133A (es)
PE (1) PE20140788A1 (es)
TN (1) TN2013000471A1 (es)
TW (1) TW201302711A (es)
WO (1) WO2012174176A1 (es)
ZA (1) ZA201308942B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
WO2012087861A1 (en) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as crth2 receptor modulators
EP2922539B1 (en) 2012-10-01 2020-01-15 Merck Sharp & Dohme Corp. Substituted isoquinolines as crth2 receptor modulators
CN104761437B (zh) * 2015-03-31 2018-06-19 上海康鹏化学有限公司 一种4-溴-2,6-二氟三氟甲氧基苯的制备方法
CN104829556B (zh) * 2015-05-06 2018-01-23 南京信息工程大学 一种由固体光气和氨基硫脲反应制备2‑羟基‑5‑氨基‑1,3,4‑噻二唑的方法
KR20180033235A (ko) 2015-07-23 2018-04-02 머크 샤프 앤드 돔 코포레이션 Crth2 수용체 길항제에 대한 반응과 연관된 유전자 마커
JP7122499B2 (ja) * 2016-06-03 2022-08-22 幸久 村田 がん転移阻害剤
WO2024124287A1 (en) * 2022-12-12 2024-06-20 The Walter And Eliza Hall Institute Of Medical Research Compounds for treating viral infection

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
WO1996001644A1 (en) 1994-07-11 1996-01-25 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5925527A (en) 1997-02-04 1999-07-20 Trega Biosciences, Inc. Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
EP1221439B1 (en) * 1999-10-14 2007-01-03 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
FR2825092B1 (fr) 2001-05-23 2005-01-14 Servier Lab Nouveau derives trycicliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
WO2004032848A2 (en) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003301299A1 (en) 2002-10-15 2004-05-04 Janssen Pharmaceutica, N.V. Benzyl substituted (piperidin-4-yl) aminobenzamido derivatives as delta-opiod receptor modulators
MXPA05003660A (es) * 2002-10-21 2005-06-08 Warner Lambert Co Derivados de quinolina como antagonistas de crth2.
CA2528774A1 (en) 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
WO2005007094A2 (en) 2003-07-09 2005-01-27 Tularik Inc. Asthma and allergic inflammation modulators
KR20070002085A (ko) 2004-04-07 2007-01-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질병을 치료하기 위한 ｐｇｄ２ 수용체 길항제
KR101329903B1 (ko) * 2004-12-27 2013-11-14 액테리온 파마슈티칼 리미티드 Ｃｒｔｈ2 수용체 길항제로서의2,3,4,9-테트라하이드로-1ｈ-카르바졸유도체
UA90706C2 (ru) * 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
ES2443022T3 (es) 2005-08-12 2014-02-17 Merck Frosst Canada Inc. Derivados de indol como antagonistas del receptor CRTH2
US8546422B2 (en) 2008-09-22 2013-10-01 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
CA2737460C (en) 2008-09-22 2016-12-20 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists
EP2346865B1 (en) 2008-09-22 2015-07-15 Merck Canada Inc. Indole derivatives as crth2 receptor antagonists
BRPI1008906B1 (pt) * 2009-02-24 2019-10-15 Merck Sharp & Dohme Corp. Composto, composição farmacêutica, e, uso de um composto
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
WO2012087861A1 (en) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as crth2 receptor modulators
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators

Also Published As

Publication number Publication date
EA201490031A1 (ru) 2014-12-30
AU2012271661A8 (en) 2016-11-10
KR20140025576A (ko) 2014-03-04
CN103763924A (zh) 2014-04-30
CA2838731A1 (en) 2012-12-20
CO6821958A2 (es) 2013-12-31
MA35188B1 (fr) 2014-06-02
MX2013014900A (es) 2014-02-17
EP2720545A4 (en) 2015-01-14
IL229508A0 (en) 2014-01-30
US20140128367A1 (en) 2014-05-08
CL2013003625A1 (es) 2014-08-01
ECSP14013156A (es) 2014-02-28
TN2013000471A1 (en) 2015-03-30
ZA201308942B (en) 2015-05-27
US8592383B2 (en) 2013-11-26
JP2014517041A (ja) 2014-07-17
NI201300133A (es) 2014-02-28
KR101599157B1 (ko) 2016-03-02
EP2720545B1 (en) 2016-11-30
EP2720545A1 (en) 2014-04-23
AU2012271661A1 (en) 2014-01-16
TW201302711A (zh) 2013-01-16
CR20130670A (es) 2014-02-04
WO2012174176A1 (en) 2012-12-20
CN103763924B (zh) 2016-05-18
PE20140788A1 (es) 2014-07-09
US20120329743A1 (en) 2012-12-27
AU2012271661B2 (en) 2016-11-03
CA2838731C (en) 2016-08-16
ES2613644T3 (es) 2017-05-25
BR112013032557A2 (pt) 2020-09-24
AU2012271661B8 (en) 2016-11-10
DOP2013000306A (es) 2014-06-01
JP5629403B2 (ja) 2014-11-19
EA025100B1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
AR086931A1 (es) Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth
AR084573A1 (es) Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth
AR086198A1 (es) Inhibidores sustituidos de acetil-coa carboxilasa y composiciones farmaceuticas que los contienen
AR105820A1 (es) Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5
AR085893A1 (es) Pirrolopirazina-amidas de piperidina espirociclica como moduladores de los canales ionicos
AR067757A1 (es) Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales.
PE20190329A1 (es) Compuestos moduladores de fxr (nr1h4)
AR084425A1 (es) Derivados heterociclicos de 8-azabiciclo[3.2.1]octan-8-ilo, composiciones farmaceuticas que los contienen, proceso para prepararlos e intermediarios y uso de los mismos para tratar patologias hepaticas tales como dislipemias e hipercolesterolemia entre otras
AR086019A1 (es) COMPUESTOS DE PIRROLO SULFONAMIDA PARA MODULACION DE LA ACTIVIDAD DEL RECEPTOR HUERFANO g RELACIONADO AL RECEPTOR NUCLEAR HUERFANO RAR (RORg, NR1F3) Y PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y AUTOINMUNES CRONICAS
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
AR088828A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
AR083872A1 (es) Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR074109A1 (es) Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil.
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR089285A1 (es) Derivados de betulina
PE20170682A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias
AR075383A1 (es) Derivados de triazolo[4,3-b]piridazina
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR060903A1 (es) Derivados de 1,2,3,4-tetrahidro-quinolina como inhibidores de cetp
AR112468A1 (es) Carboxamidas como inhibidores de proteasa específicos de ubiquitina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal